On October 26, 2011, the Canadian Agency for Drugs and Technologies in Health (CADTH) signed an agreement with the Pan American Health Organization (PAHO), granting PAHO permission to translate the Rx for Change database into Spanish. This agreement will make the unique database available to the Americas and potentially improve the prescribing practice and use of drugs and other health technologies in these regions.
Potential for patient falls or unanticipated patient movement, which may result in serious injury or death.
The ACCORD Lipid trial found no significant difference in the risk of a major adverse cardiac event between group treated with fenofibrate plus simvastatin compared with simvastatin alone.
Failure to adequately ventilate may lead to hypoxia or hypercarbia, which may result in serious neurological injury or death.
OTTAWA — The Canadian Agency for Drugs and Technologies in Health (CADTH) today announced the appointment of a Public Member to its recently established Health Technology Expert Review Panel. The Panel is an advisory body, convened to develop guidance and recommendations to CADTH on non-drug health technologies such as medical devices. The Panel consists of Core Members, who are appointed to serve for all topics under consideration, and Expert Members, who are appointed on a per-project basis, providing expertise on specific topics.
OTTAWA — The Canadian Agency for Drugs and Technologies in Health (CADTH) today announced the appointment of a Public Member to its recently established Health Technology Expert Review Panel. The Panel is an advisory body, convened to develop guidance and recommendations to CADTH on non-drug health technologies such as medical devices. The Panel consists of Core Members, who are appointed to serve for all topics under consideration, and Expert Members, who are appointed on a per-project basis, providing expertise on specific topics.
Just in time for Diabetes Awareness Month, today CADTH launches its updated virtual library of diabetes reports, tools, and other resources — conveniently collecting them in one place.
Just in time for Diabetes Awareness Month, today CADTH launches its updated virtual library of diabetes reports, tools, and other resources — conveniently collecting them in one place.
Disponibili on line nuove ed importanti informazioni riguardanti il ritiro dal mercato di XIGRIS® (drotrecogin alfa – attivato).
Disponibili on line nuove ed importanti informazioni di sicurezza circa le controindicazioni all’uso di OZOPULMIN supposte, contenente derivati terpenici.
80.211.154.110
